EP300.md
... ...
@@ -9,7 +9,7 @@ link-citations: true
9 9
Mutations in EP300 are significant contributors to the pathogenesis and progression of B-cell lymphomas such as DLBCL and FL.[@pasqualucciInactivatingMutationsAcetyltransferase2011] This gene has some recurrent sites of mutations (hot spots), which typically impact its HAT domain, a region crucial for acetylating histones and non-histone proteins.[@pasqualucciInactivatingMutationsAcetyltransferase2011]
10 10
11 11
## Experimental Evidence
12
-EP300 mutations impair histone acetylation, disrupt epigenetic gene regulation. Mutations in CREBBP and EP300 affect a common pathway and have been described as mutually exclusive due to some functional redundancy.[@pasqualucciInactivatingMutationsAcetyltransferase2011a; @veazeyCARM1InhibitionReduces2020b]
12
+EP300 mutations impair histone acetylation, disrupt epigenetic gene regulation. Mutations in CREBBP and EP300 affect a common pathway and have been described as mutually exclusive due to some functional redundancy.[@pasqualucciInactivatingMutationsAcetyltransferase2011; @veazeyCARM1InhibitionReduces2020]
13 13
Studies using genome-wide CRISPR-Cas9 screens have identified synthetic lethal interactions between CREBBP and EP300, suggesting that targeting one may affect the viability of cells with mutations in the other.[@nieGenomewideCRISPRScreens2021]
14 14
15 15
## History
... ...
@@ -30,9 +30,9 @@ timeline
30 30
31 31
|Entity|Tier|Description |
32 32
|:------:|:----:|--------------------------------------|
33
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiCodingGenomeSplenic2012c]|
34
-|![DLBCL](images/icons/DLBCL_tier1.png) |1-EE |high-confidence DLBCL gene supported by functional data [@pasqualucciInactivatingMutationsAcetyltransferase2011a]|
35
-|![FL](images/icons/FL_tier1.png) |1-EE |high-confidence FL gene supported by functional data [@pasqualucciInactivatingMutationsAcetyltransferase2011a]|
33
+|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiCodingGenomeSplenic2012]|
34
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-EE |high-confidence DLBCL gene supported by functional data [@pasqualucciInactivatingMutationsAcetyltransferase2011]|
35
+|![FL](images/icons/FL_tier1.png) |1-EE |high-confidence FL gene supported by functional data [@pasqualucciInactivatingMutationsAcetyltransferase2011]|
36 36
37 37
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
38 38
FAS.md
... ...
@@ -31,7 +31,7 @@ timeline
31 31
|Entity|Tier|Description |
32 32
|:------:|:----:|--------------------------------------|
33 33
|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
34
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@spinaGeneticsNodalMarginal2016b]|
34
+|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@spinaGeneticsNodalMarginal2016]|
35 35
|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@schollMutationsRegionFAS2007]|
36 36
|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
37 37
HIST1H1D.md
... ...
@@ -6,7 +6,7 @@ link-citations: true
6 6
# HIST1H1D
7 7
8 8
## Overview
9
-This is one of several genes that encode linker histone proteins that are recurrently mutated in DLBCL and FL.[@morinMutationalStructuralAnalysis2013; @krysiakRecurrentSomaticMutations2017b]
9
+This is one of several genes that encode linker histone proteins that are recurrently mutated in DLBCL and FL.[@morinMutationalStructuralAnalysis2013; @krysiakRecurrentSomaticMutations2017]
10 10
Mutations are often found in the globular domain of the protein, which is critical for its interaction with DNA and other histone proteins.
11 11
12 12
## History
HIST1H1E.md
... ...
@@ -25,9 +25,9 @@ timeline
25 25
26 26
|Entity|Tier|Description |
27 27
|:------:|:----:|--------------------------------------|
28
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015a]|
29
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012a]|
30
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017b]|
28
+|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015]|
29
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012]|
30
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
31 31
|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@grandeGenomewideDiscoverySomatic2019]|
32 32
33 33
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST1H2AC.md
... ...
@@ -21,7 +21,7 @@ timeline
21 21
22 22
|Entity|Tier|Description |
23 23
|:------:|:----:|--------------------------|
24
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinMutationalStructuralAnalysis2013; @chapuyMolecularSubtypesDiffuse2018b; @hubschmannMutationalMechanismsShaping2021b]|
24
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinMutationalStructuralAnalysis2013; @chapuyMolecularSubtypesDiffuse2018; @hubschmannMutationalMechanismsShaping2021]|
25 25
|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
26 26
27 27
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
ID3.md
... ...
@@ -22,8 +22,8 @@ The existence of mutations in DLBCL were described in 2012 by Schmitz et al[@sch
22 22
23 23
|Entity|Tier|Description |
24 24
|:------:|:----:|-----------------------------------------|
25
-|![BL](images/icons/BL_tier1.png) |1 | high-confidence BL gene [@richterRecurrentMutationID32012a]|
26
-|![MZL](images/icons/MZL_tier1.png) |1 | high-confidence MZL gene [@spinaGeneticsNodalMarginal2016b]|
25
+|![BL](images/icons/BL_tier1.png) |1 | high-confidence BL gene [@richterRecurrentMutationID32012]|
26
+|![MZL](images/icons/MZL_tier1.png) |1 | high-confidence MZL gene [@spinaGeneticsNodalMarginal2016]|
27 27
|![DLBCL](images/icons/DLBCL_tier2.png) |2 | Although recurrent, the relevance of mutations in DLBCL is tenuous[@schmitzBurkittLymphomaPathogenesis2012]|
28 28
29 29
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
JUNB.md
... ...
@@ -24,7 +24,7 @@ timeline
24 24
|Entity|Tier|Description |
25 25
|:------:|:----:|--------------------------|
26 26
|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
27
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017; @hubschmannMutationalMechanismsShaping2021b]|
27
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017; @hubschmannMutationalMechanismsShaping2021]|
28 28
29 29
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
30 30
MAP7D1.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|--------------------------------------|
20
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023b]|
20
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
MCL1.md
... ...
@@ -24,7 +24,7 @@ timeline
24 24
25 25
|Entity|Tier|Description |
26 26
|:------:|:----:|--------------------------------------|
27
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021b]|
27
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021]|
28 28
|![BL](images/icons/BL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@paneaWholeGenomeLandscape2019]|
29 29
|![DLBCL](images/icons/DLBCL_tier1.png) |1-a | aSHM target and high-confidence DLBCL gene [@reddyGeneticFunctionalDrivers2017]|
30 30